|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute on Deafness and Other Communication Disorders (NIDCD) |
| Information provided by: | National Institutes of Health Clinical Center (CC) |
| ClinicalTrials.gov Identifier: | NCT00023036 |
Purpose
This study will try to identify and understand the genetic factors that lead to inner ear malformation called "enlarged vestibular aqueducts", that can lead to hearing loss.
Patients with sensorineural hearing loss with or without inner ear malformations and their parents and siblings may be eligible for this study. Participants and their immediate family members, may undergo some or all of the following tests and procedures:
| Condition |
|
Sensorineural Hearing Loss Cytomegalovirus Infection |
| Genetics Home Reference related topics: | nonsyndromic deafness |
| MedlinePlus related topics: | Cytomegalovirus Infections Hearing Disorders and Deafness |
| Study Type: | Observational |
| Study Design: | Other |
| Official Title: | Clinical and Molecular Analysis of Enlarged Vestibular Aqueducts |
| Estimated Enrollment: | 500 |
| Study Start Date: | August 2001 |
Nonsyndromic hereditary hearing impairment is a genetically heterogeneous disorder that can be caused by mutations in any one of at least 60 different genes. Enlargement of the vestibular aqueduct (EVA) is a radiologic finding known to be associated with mutations in one of these genes, the Pendred syndrome gene (PDS). EVA may thus serve as a clinically useful marker to facilitate the diagnosis of hearing impairment. Recent data from our laboratory and others indicates that only a subset of individuals with EVA have PDS mutations, and therefore some EVA cases are likely to be caused by other genes, nongenetic factors, or a combination of these etiologies. Individuals with hearing impairment and EVA will be enrolled in this study in order to: (1) Prospectively determine the prevalence of PDS mutation in EVA patients; (2) correlate phenotypic features with PDS genotype status; 3) identify other genetic factors that cause EVA. Siblings and parents may also be enrolled in order to define inheritance and to perform molecular genetic analyses.
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Patients with known or suspected nonsyndromic SNHL associated with inner ear malformations will be recruited.
Eligibility requires two or more participating affected family members since they are needed for gentic mapping approaches to identify genes in which mutations cause EVA, with the exception of sporadic cases with distinctive phenotypic features that may provide insight in to novel etiolgoies of EVA.
Siblings and biological parents of study subjects with SNHL and inner ear malformations will also be eligible in order to identify subclinical phenotypes, determine the mode of inheritance, and facilitate the molecular genetic analyses.
Referrals will be accepted from otolaryngologists, audiologists, medical geneticists, genetic counselors, other health care professionals, as well as self-referrals from potiential study subjects and their family members. Given the rarity of these disorders, referrals will be accepted worldwide and subjects from all ethnic backgrounds will be recruited.
EXCLUSION CRITERIA:
Patients known to be exposed to physical or chemical teratogens in utero may be excluded because their inner ear malformations could be due to these nongenetic etiologies (e.g., thalidomide, radiation, etc.).
Hearing loss that is associated with previously described syndromes such as bronchio-oto-renal (BOR) syndrome.
Contacts and Locations| Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
| Contact: TTY | 1-866-411-1010 |
| United States, Alabama | |||||
| University of Alabama | Recruiting | ||||
| Birmingham, Alabama, United States | |||||
| United States, Maryland | |||||
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting | ||||
| Bethesda, Maryland, United States, 20892 | |||||
More Information
NIH Clinical Center Detailed Web Page 
  |
| Study ID Numbers: | 010228, 01-DC-0228 |
| First Received: | August 21, 2001 |
| Last Updated: | September 5, 2008 |
| ClinicalTrials.gov Identifier: | NCT00023036 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|